Introduction
============

The incidence of metastatic ovarian cancer varies greatly across different studies (it was reported to occur in 2.3 to 23.7% of cases of malignant ovarian cancer). Such tumors mainly arise from the colon (10.9 to 33.2%), breast (1.8 to 33.3%), or stomach (4.5 to 30.4%) ([@b1-ol-0-0-9467]). Metastatic ovarian cancer occurs in 5 to 9.7% of women with colorectal cancer, who exhibit a median survival period of only 19 to 27 months after detection ([@b2-ol-0-0-9467],[@b3-ol-0-0-9467]). Surgical treatment has been recommended in several retrospective studies because it results in a better prognosis ([@b4-ol-0-0-9467]--[@b6-ol-0-0-9467]), and chemotherapy exhibits poor sensitivity, although recurrence and distant metastasis often occur during the follow-up period. Furthermore, the preoperative clinical diagnosis of metastatic ovarian cancer is difficult, and pathological examinations of surgical samples are required to definitively differentiate it from primary ovarian cancer. In previous studies of its utility for distinguishing primary ovarian cancer from metastatic ovarian cancer, imaging analysis was shown to only produce non-specific findings ([@b7-ol-0-0-9467],[@b8-ol-0-0-9467]).

Despite recent progress in colorectal cancer treatment, including the development of molecular-targeting therapy, there are little available data about the best way to treat patients affected by metastatic colorectal cancer to the ovary. Furthermore, there is insufficient information about the clinicopathological and genomic predictors of the outcomes of such patients, and the optimal clinical management strategy remains unclear ([@b9-ol-0-0-9467],[@b10-ol-0-0-9467]). Ganesh *et al* ([@b9-ol-0-0-9467]), examined the genetic aberrations found in metastatic colorectal cancer to the ovary, including primary colorectal cancer, ovarian metastasis, and extra-ovarian metastasis. The frequencies of somatic mutations in oncogenes and tumor suppressor genes demonstrated a high concordance rate between matched primary and metastatic (from sites other than the ovary) colorectal tumors. Increased frequencies of mutations were seen in the Kirsten rat sarcoma viral oncogene homolog (*KRAS*), Smad family member 4 (*SMAD4*), and neurotrophic receptor tyrosine kinase 1 (*NTRK1*) genes.

Recent studies have shown that genomic alterations in solid cancers can be characterized by massive parallel sequencing of the circulating cell-free tumor DNA released from cancer cells in plasma, which is known as circulating tumor DNA (ctDNA). This technique is effectively a non-invasive 'liquid biopsy' examination ([@b11-ol-0-0-9467],[@b12-ol-0-0-9467]). Liquid biopsy examinations of ctDNA can be used to detect molecular alterations, including tumor-specific mutations, and have recently been used as a diagnostic, prognostic, and predictive tool, especially in colorectal cancer (to detect *RAS* mutations) and lung cancer (to detect epidermal growth factor receptor \[*EGFR*\] mutations) ([@b13-ol-0-0-9467]--[@b15-ol-0-0-9467]). However, to the best of our knowledge, there have not been any reports about the use of liquid biopsy examinations in patients with metastatic colorectal cancer to the ovary. In this study, we subjected plasma ctDNA samples (liquid biopsy samples) to multiple gene mutation analysis using CAncer Personalized Profiling by deep Sequencing (CAPP-Seq), a novel next-generation sequencing-based approach to ultrasensitive ctDNA detection ([@b16-ol-0-0-9467],[@b17-ol-0-0-9467]), in patients with ovarian metastases from colorectal cancer. Then, we compared the findings with the results obtained for primary and metastatic tumor samples.

Materials and methods
=====================

### Patients and samples

Two patients whose metastatic ovarian tumors had been surgically resected at Wakayama Medical University Hospital between May 2017 and June 2017 were included in this study. The tumor staging was carried out according to the TNM classification. The present study was approved by the ethics committee of Wakayama Medical University Faculty of Medicine (authorization no: 2025) and Kindai University Faculty of Medicine (authorization no: 29-066). All of the patients in this study provided written informed consent for the use of their plasma and tissue samples.

### Tumor DNA extraction

Formalin-fixed paraffin-embedded (FFPE) specimens were subjected to a histological review, and only those containing sufficient tumor cells (at least 75% tumor cells), as determined by hematoxylin and eosin staining, were used for DNA extraction. The collected DNA was purified with the use of an AllPrep DNA/RNA FFPE kit (Qiagen, Inc., Valencia, CA, USA), according to the manufacturer\'s instructions. The quality and quantity of the DNA were verified using the NanoDrop 2000 device (Thermo Fisher Scientific, Inc., Wilmington, DE, USA) and PicoGreen dsDNA assay kit (Thermo Fisher Scientific, Inc.). The extracted DNA was stored at −80°C until the analysis.

### Tumor DNA sequencing

We used a 40 ng of DNA for the QIAseq Human Comprehensive Cancer Panel (275 genes; Qiagen, Inc.). Library preparation was performed according to the manufacturer\'s instructions. The purified libraries were pooled and then sequenced with a NextSeq 500 instrument (Illumina, Inc., San Diego, CA, USA). Reads were aligned with the hg19 human reference genome, and variant detection was performed according to the manufacturer\'s pipeline ([@b18-ol-0-0-9467]). Germline mutations were excluded with the use of the Human Genetic Variation Database (<http://www.genome.med.kyoto-u.ac.jp/SnpDB>) and the Exome Aggregation Consortium database ([@b19-ol-0-0-9467]).

### ctDNA extraction

Samples (8.5 ml) of peripheral blood were collected from the patients in cell-free DNA collection tubes (Roche Diagnostics, Indianapolis, IN, USA). Plasma ctDNA was purified using an AVENIO cfDNA isolation kit (Roche Diagnostics), according to the manufacturer\'s instructions. The quality and quantity of the DNA were verified using the NanoDrop 2000 device (Thermo Fisher Scientific, Inc.) and PicoGreen dsDNA assay kit (Thermo Fisher Scientific, Inc.). The extracted ctDNA was stored at −80°C until the analysis.

### ctDNA sequencing

We used a maximum of 50 ng of DNA for the CAPP-Seq ctDNA analyses using the AVENIO ctDNA surveillance kit (197 genes; Roche Diagnostics), according to the manufacturer\'s instructions. The purified libraries were pooled and sequenced on an Illumina NextSeq 500 (Illumina, Inc.) using the 300-cycle high output kit. Variants were called with the AVENIO ctDNA analysis software (Roche Diagnostics), which includes bioinformatics methods from CAPP-Seq ([@b16-ol-0-0-9467]) and integrated digital error suppression ([@b17-ol-0-0-9467]). Germline mutations were excluded with the use of the Human Genetic Variation Database (<http://www.genome.med.kyoto-u.ac.jp/SnpDB>) and the Exome Aggregation Consortium database ([@b19-ol-0-0-9467]).

Results
=======

### Patient 1

A 61-year-old female was referred to our institution with suspected ovarian cancer. She had been diagnosed with sigmoid colon cancer 2 years ago, which was completely surgically resected in other institution. The tumor had a moderately differentiated histology, and pathologically, it extended into the subserosa (pT3). There were no lymph node or distant metastases (pN0, M0). The patient received adjuvant chemotherapy (8 courses of capecitabine). Two years later, a tumor appeared in the right ovary. Magnetic resonance imaging (MRI) revealed a solid 4.3-cm mass with an irregular surface, and positron emission tomography-computed tomography (PET-CT) detected high radiotracer uptake by the tumor \[maximum standardized uptake value (SUVmax): 10.66\]. The patient\'s levels of carcinoembryonic antigen (CEA) and cancer antigen (CA) 19-9 were elevated (to 8.8 ng/ml and 58.4 U/ml, respectively), whereas her CA125 level was normal. The patient underwent a total abdominal hysterectomy and bilateral salpingo-oophorectomy, and the pathological diagnosis was metastatic ovarian cancer. We obtained an FFPE sample from the metastatic ovarian tumor (O-1) and a preoperative plasma ctDNA sample (L-1). The patient\'s clinical course and clinicopathological features are summarized in [Fig. 1A](#f1-ol-0-0-9467){ref-type="fig"}. Targeted re-sequencing was performed using the QIAseq Human Comprehensive Cancer Panel for O-1 and the AVENIO ctDNA surveillance kit for L-1. Intronic changes and exonic SNP listed in the HGVD database were excluded from our analysis, as described in Materials and Methods. Non-synonymous somatic point mutations that resulted in changes in protein amino acid sequences are summarized in [Table I](#tI-ol-0-0-9467){ref-type="table"}. In O-1, mutations were identified in three regions, the *KRAS* G13D, adenomatous polyposis coli (APC) E1306\*, and tumor protein p53 (TP53) H193Y genes. Sequencing of the plasma ctDNA detected three mutations and one copy number variation; i.e., *KRAS* G13D, *APC* E1306\*, and *TP53* H193Y mutations and MET gene amplification. A comparison of the genetic profiles of O-1 and L-1 revealed that the *KRAS* G13D, *APC* E1306\*, and *TP53* H193Y gene mutations, which are well-known genetic signatures of colorectal cancer were present in both O-1 and L-1. These results suggest that liquid biopsy-based gene mutation profiling could facilitate the preoperative diagnosis of metastatic colorectal cancer to the ovary. The patient received postoperative adjuvant chemotherapy (8 courses of capecitabine and oxaliplatin; XELOX).

### Patient 2

A 66-year-old female was referred to our institution with suspected ovarian cancer. She had been diagnosed with transverse colon cancer 2 years earlier, which was completely surgically resected. The tumor had a well-differentiated histology, and pathologically, it extended into the subserosa (pT3). There was a single lymph node metastasis, but no distant metastasis (pN1a, M0). The patient was treated with adjuvant chemotherapy (8 courses of capecitabine). Two years later, a tumor appeared in the right ovary. MRI revealed a multilocular, partially solid, 5.0-cm mass with an irregular surface, and PET-CT detected high radiotracer uptake by the tumor (SUVmax: 6.39). The patient\'s CEA level was elevated (11.1 ng/ml), while her CA19-9 and CA125 levels were normal. She underwent a total abdominal hysterectomy and bilateral salpingo-oophorectomy, and the pathological diagnosis was metastatic ovarian cancer. We obtained an FFPE sample of the primary transverse colon cancer (P-2), an FFPE sample of the metastatic ovarian tumor (O-2), and a plasma ctDNA sample before the second operation (L-2). The patient\'s clinical course and clinicopathological features are summarized in [Fig. 1B](#f1-ol-0-0-9467){ref-type="fig"}. Targeted re-sequencing was performed using the QIAseq Human Comprehensive Cancer Panel for the FFPE samples and the AVENIO ctDNA surveillance kit for the plasma ctDNA. The intronic changes and exonic SNP listed in the HGVD database were excluded from our analysis, as described in Materials and Methods. The non-synonymous somatic point mutations that resulted in changes in protein amino acid sequences are summarized in [Table II](#tII-ol-0-0-9467){ref-type="table"}. Mutations were identified in the same region; i.e., *APC* R216\* and *TP53* L257P, in both the primary (P-2) and metastatic (O-2) tumors. Sequencing of the plasma ctDNA sample (L-2) detected a single mutation: *APC* R216\*. In a comparison of the genetic profiles of P-2, O-2, and L-2, it was found that *APC* R216\* was present in all P-2, O-2, and L-2, whereas it was not detected in L-2. Conversely *APC* R216\* was detected in L-2, which is well-known genetic signature of colorectal cancer. These findings also support the usefulness of liquid biopsy-based gene mutation profiling in the preoperative diagnosis of metastatic colorectal cancer to the ovary. The patient received postoperative adjuvant chemotherapy (8 courses of capecitabine and oxaliplatin; XELOX).

Discussion
==========

To the best of our knowledge, the current study is the first to characterize the genetic profile of metastatic colorectal cancer to the ovary, by subjecting liquid biopsy samples to a novel comprehensive gene mutation analysis technique; i.e., CAPP-Seq. We investigated the mutation profiles of tumor and liquid samples of metastatic colorectal cancer to the ovary to elucidate the potential of liquid biopsy examinations as a tool for preoperative diagnosis. In comparisons of the mutation profiles of the patients\' tumor and liquid samples, matching colorectal cancer mutation signatures were observed in both patients, suggesting that liquid biopsy has potential as a tool for aiding the preoperative diagnosis and treatment of metastatic ovarian cancer from colorectal cancer.

Liquid biopsy examinations are non-invasive and have the potential to improve cancer (including recurrence) detection, non-invasive tumor genotyping, and disease monitoring. However, most early-stage and many advanced-stage solid tumors exhibit very low levels of ctDNA, which complicates ctDNA detection and analysis. In this study, we used CAPP-Seq, a novel approach which combines the hybrid affinity capture of hundreds of genomic regions with deep sequencing and a specialized bioinformatics workflow, for the ultrasensitive quantitation of ctDNA during comprehensive gene expression analysis ([@b16-ol-0-0-9467]). CAPP-Seq is able to detect ctDNA in patients with early and advanced stages of various human malignancies, including lung cancer and lymphoma ([@b17-ol-0-0-9467],[@b20-ol-0-0-9467]). However, in the gynecological field there have not been any reports about the comprehensive gene mutation analysis of liquid biopsy samples, which might be a powerful tool for advancing personalized medicine for gynecological malignancies.

We revealed that liquid biopsy examinations have potential to facilitate the preoperative diagnosis of metastatic ovarian cancer from colorectal cancer. After examining FFPE tumor samples, Crobach *et al* reported that the gene mutation profiles of primary and metastatic ovarian cancer differ ([@b10-ol-0-0-9467]). Inactivating *APC* mutations were found in 4.7% of primary endometrioid or mucinous ovarian tumors, whereas they were identified in 71% of colorectal cancer metastases; thus, *APC* mutation analysis can be used to differentiate between primary endometrioid/mucinous ovarian tumors and colorectal cancer metastases to the ovary. In patient 1, *KRAS* G13D, *APC* E1306\*, and *TP53* H193Y mutations were detected in both O-1 and L-1, with MET gene amplification in L-1, which has been reported to be a common gene mutation pattern in colorectal cancer. In patient 2, *APC* R216\* was detected in all P-2, O-2, and L-2, which is also well-known genetic signature of colorectal cancer. These findings suggest that it might be possible to predict the development of metastatic ovarian cancer from colorectal cancer based on the detection of *APC* gene mutations in liquid biopsy samples.

The detection of *KRAS* mutations in liquid biopsy samples also plays an important role in selecting the optimal treatment for metastatic ovarian cancer from colorectal cancer. Anti-EGFR antibodies combined with cytotoxic agents are one of the standard treatments for advanced colorectal cancer. Although the addition of anti-EGFR antibodies was found to be related to a significantly reduced risk of disease progression and improved overall survival in patients with *KRAS* wild-type tumors, this treatment had no benefit in patients whose tumors carried *KRAS* gene mutations in codons 12 and 13 ([@b21-ol-0-0-9467],[@b22-ol-0-0-9467]) Furthermore, less favorable clinical outcomes, particularly shorter survival, have been reported to be associated with the presence of *KRAS* mutations in codon 13 ([@b23-ol-0-0-9467]). Thus, *KRAS* mutation status was confirmed to be a powerful biomarker for predicting the efficacy of anti-EGFR antibody treatment ([@b24-ol-0-0-9467]). In patient 1, a *KRAS* G13D mutation, which confers resistance to anti-EGFR antibodies and is associated with greater progression, was detected in the liquid biopsy sample.

Tumor heterogeneity might also hinder personalized molecular-targeted treatment, which depends on patients\' somatic mutation profiles. In a previous study, we detected intra- and inter-tumor multi-clonality during mutational profiling of multi-regional colon cancer using next-generation sequencing of FFPE tumor samples ([@b25-ol-0-0-9467]). The *KRAS-NRAS* status of a tumor can vary between regions, making it difficult to decide whether anti-EGFR antibodies should be used. Examining tumor heterogeneity is challenging because we can not use whole surgically resected tumor samples for gene mutation analysis, and collecting tumor samples can be difficult in advanced cases involving repeated biopsies. In another previous study, by using liquid biopsy, we also detected newly appearing *KRAS-NRAS* mutation after first-line chemotherapy in metastatic colorectal cancer with wild-type of *KRAS* exon 2 in tumor tissue at the diagnosis, which could be a negative predictive marker for panitumumab (anti-EGFR antibody) ([@b26-ol-0-0-9467]). Non-invasive liquid biopsy examinations, whose results are not influenced by tumor heterogeneity, might be useful for determining the optimal chemotherapy regimen, including for novel molecular-targeted agents, immediately just before the treatment.

In conclusion, this is the first study to examine the tumor gene mutation profile of metastatic colorectal cancer to the ovary using both tumor and liquid samples. The difficulty of obtaining a preoperative diagnosis and tumor heterogeneity can both influence the effectiveness of molecular-targeted agents, such as anti-EGFR antibodies. Thus, in the clinical setting liquid biopsy examinations, which are non-invasive and easy to perform repeatedly, might be useful. The characterization of the genetic profiles of tumors based on liquid biopsy examinations might lead to the development of novel personalized treatment strategies. To confirm the findings of this study, a further investigation should be conducted.
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![Treatment timelines for the two patients. (A) Patient 1 (a 61-year-old female) had previously been diagnosed with sigmoid colon cancer, which was surgically resected. The patient received adjuvant chemotherapy (8 courses of capecitabine). Two years later, ovarian metastasis was detected, and the patient underwent surgical resection (O-1), followed by adjuvant chemotherapy (8 courses of XELOX). A liquid sample (plasma) was collected preoperatively (L-1). (B) Patient 2 (a 66-year-old female) had previously been diagnosed with primary transverse colon cancer, which was surgically resected (P-2). The patient received adjuvant chemotherapy (8 courses of capecitabine). Two years later, ovarian metastasis was detected, and the patient underwent surgical resection (O-2), followed by adjuvant chemotherapy (8 courses of XELOX). A liquid sample (plasma) was collected preoperatively (L-2).](ol-16-05-6431-g00){#f1-ol-0-0-9467}

###### 

Non-synonymous mutations in Patient 1.

                                                  Variant frequency (%)   
  ------- ----------- ------ ---------- --------- ----------------------- ------
  Chr5    112839510   APC    Nonsense   E1306\*   11.85                   41.2
  Chr12   25245347    KRAS   Missense   G13D      7.58                    26.0
  Chr17   7674954     TP53   Missense   H193Y     9.48                    41.0

Chr, chromosome.

###### 

Non-synonymous mutations in Patient 2.

                                                 Variant frequency (%)          
  ------- ----------- ------ ---------- -------- ----------------------- ------ ------
  Chr5    112792446   APC    Nonsense   R216\*   17.2                    0.11   20.3
  Chr17   7577511     TP53   Missense   L257P    23.6                    0      28.5

Chr, chromosome.
